Arixtra

The recommended dose of Arixtra (Fondaparinux) depends on the reason the medication is being used. The dose is injected subcutaneously or SC (under the skin), once daily. Sometimes, in a hospital setting, Arixtra (Fondaparinux) is given intravenously (into the vein).

To prevent clots after surgery, the dose is 2.5 mg injected once daily starting at least 6 hours after surgery.

When treating DVT or PE, the dose depends on body weight and ranges from 5 mg to 10 mg injected SC once daily.

For the management of heart attacks or severe angina, the dose is 2.5 mg SC once daily.

In all cases, it is important to continue using Arixtra (Fondaparinux) until your doctor has determined that the risk of blood clots has passed. This may be because you are mobile again after surgery or because another medication has been introduced to continue the clot prevention.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.

If you are injecting Arixtra (Fondaparinux) yourself, your doctor will show you how to use Arixtra (Fondaparinux) properly. If you are not sure how to use it or have questions about how to use it, contact your doctor. Before using Arixtra (Fondaparinux), thoroughly read the patient information provided and ask your doctor if you have any questions. If a caregiver will be giving you the injections, your doctor should instruct them on how to give the injection.

To use Arixtra (Fondaparinux):

• Wash your hands and clean the injection site with an alcohol swab. Do not rub the injection site. Do not use it if the syringe is leaky, or if the medication appears cloudy or discoloured.
• Remove the needle shield. Avoid pressing on the syringe plunger so as not to lose any of the syringe content. Hold the syringe like a pencil.
• Pinch a fold of skin in the lower (left or right) region of your abdomen. Choose a different injection site for each injection so that you are not always injecting the same area.
• While holding the skin fold, insert the entire needle into the skin fold at a 90° angle to the skin and depress the syringe plunger completely.
• Remove the needle and let go of the syringe plunger. (The syringe will move into the device until the needle is guarded.)
• Apply pressure to the injection site with the alcohol swab for 5 to 10 seconds. Do not rub the injection site.
• Safely dispose of the used syringe device in approved containers, and keep it out of the reach of children.

It is important to take Arixtra (Fondaparinux) exactly as prescribed by your doctor. If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.

Store Arixtra (Fondaparinux) at room temperature and keep out of reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

2.5 mg/0.5 mL
Each 0.5 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 2.5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.

5 mg/0.4 mL
Each 0.4 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.

7.5 mg/0.6 mL
Each 0.6 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 7.5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.

10 mg/0.8 mL
Each 0.8 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 10 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.

Do not take Arixtra (Fondaparinux) if you:

• are allergic to Arixtra (Fondaparinux) or any ingredients of the medication
• have excessive bleeding
• have a bacterial infection of the heart or heart valves
• have a low level of platelets in the blood and anti-platelet antibodies

There may be an interaction between Arixtra (Fondaparinux) and any of the following:

• acetylsalicylic acid (Asa)
• alteplase
• Apixaban
• Clopidogrel
• dabigatran
• Dasatinib
• Deferasirox
• Dipyridamole
• Edoxaban
• estrogens (e.g., conjugated estrogen, Estradiol, ethinyl estradiol)
• Heparin
• herbal products that affect blood clotting (e.g., cat's claw, chamomile, fenugreek, evening primrose, feverfew, garlic, ginger, ginseng, turmeric)
• Ibrutinib
• low-molecular-weight heparins (e.g., Dalteparin, Enoxaparin, Tinzaparin)
• mifepristone
• Obinutuzumab
• omega-3 fatty acids
• non-steroidal anti-inflammatory medications (NSAIDs; e.g., Diclofenac, ibuprofen, naproxen)
• Prasugrel
• progestins (e.g., Dienogest, Levonorgestrel, medroxyprogesterone, Norethindrone)
• Rivaroxaban
• selective serotonin reuptake inhibitors (SSRIs; e.g., Citalopram, Fluoxetine, Paroxetine, Sertraline)
• serotonin-norepinephrine reuptake inhibitors (SNRIs; Desvenlafaxine, Duloxetine, Venlafaxine)
• Ticagrelor
• Ticlopidine
• tipranavir
• vitamin E
• Warfarin

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

• stop taking one of the medications,
• change one of the medications to another,
• change how you are taking one or both of the medications, or
• leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with Arixtra (Fondaparinux). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Arixtra (Fondaparinux).

Bleeding: Arixtra (Fondaparinux) can increase the risk of unwanted or uncontrolled bleeding, particularly if you have a bleeding disorder, ulcers of the digestive system or a recent episode of bleeding after brain, spine, or eye surgery. People who weigh less than 50 kg may also have an increased risk of bleeding. If you believe you may have an increased risk of bleeding problems, discuss with your doctor how Arixtra (Fondaparinux) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Arixtra (Fondaparinux), and whether any special monitoring is needed.

Kidney function: Kidney Disease or reduced kidney function may cause Arixtra (Fondaparinux) to build up in the body, causing side effects. If you have reduced kidney function or kidney disease, discuss with your doctor how Arixtra (Fondaparinux) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Arixtra (Fondaparinux), and whether any special monitoring is needed.

Latex allergy: The needle shield of the pre-filled syringe contains dry natural latex rubber. If you are allergic to latex, this may cause an allergic reaction.

Spinal/epidural hematomas: There have been cases of spinal bleeding and blood clots when antithrombotic medications are used along with spinal or epidural anesthesia. These spinal blood clots may lead to long-term or permanent paralysis. The risk may be greater if people are taking other medications that affect blood clotting (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] such as Naproxen or Ibuprofen, or other anticoagulants), or in people who require repeated epidural or spinal procedures. If you notice a sudden inability to move your body or sudden back pain or tenderness, get medical help immediately.

Pregnancy: Arixtra (Fondaparinux) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Arixtra (Fondaparinux), contact your doctor immediately.

Breast-feeding: It is not known if Arixtra (Fondaparinux) passes into breast milk. If you are a breast-feeding mother and are taking Arixtra (Fondaparinux), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

Children: The safety and effectiveness of using Arixtra (Fondaparinux) have not been established for children less than 17 years old.

Seniors: People over the age of 65 years old may be more at risk of bleeding from Arixtra (Fondaparinux).